Table 4.
The treatment characteristics of the included studies.
| Author and Year | Patients (n) | Molecular Response n/N (%) | OS (Months) (Median, Range) | PFS (Months) (Median, Range) | Treatment Related Deaths, n/N (%) |
|---|---|---|---|---|---|
| Kratochwil et al. (12) | 40 | NR | >12.0 (NR) | 7.0 (NR) | NR |
| Sathekge et al. (13) | 73 | 21/73 (29) | 18 (16.2–19.9) | 15.2 (13.1–17.4) | NR |
| van der Doelen et al. (14) | 13 | 6/7 (86) | 8.5 (NR) | 5.5 (NR) | NR |
| Satapathy et al. (15) | 11 | NR | NR | NR | 3/11 (27) |
| Feuerecker et al. (16) | 26 | NR | 7 (4.5–12.1) | 3.5 (1.8–11.2) | NR |
| Sen et al. (17) | 38 | 17/38 (45) | 12 (9.1–14.9) | 8 (5.3–10.6) | NR |
NR, not reported; OS, overall survival; PFS, progression-free survival.